Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on October 21, 2002

Hypertension. 2002
Published online before print October 21, 2002, doi: 10.1161/01.HYP.0000039963.01288.D3
A more recent version of this article appeared on December 1, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/6/880    most recent
01.HYP.0000039963.01288.D3v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Umrani, D. N.
Right arrow Articles by Lokhandwala, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Umrani, D. N.
Right arrow Articles by Lokhandwala, M. F.
Related Collections
Right arrow Obesity
Right arrow Hypertension - basic studies
Right arrow Type 2 diabetes

Submitted on May 14, 2002
Revised on June 6, 2002

Rosiglitazone Treatment Restores Renal Dopamine Receptor Function in Obese Zucker Rats

Dhananjay N. Umrani; Anees A. Banday; Tahir Hussain; and Mustafa F. Lokhandwala*

From the Heart and Kidney Institute, College of Pharmacy, University of Houston, Houston, Tex.

* To whom correspondence should be addressed. E-mail: MLokhandwala{at}uh.edu.

Abstract—Earlier we have reported a defective dopamine D1-like receptor function, which was accompanied by a decrease in D1 receptor numbers and the inability of dopamine to inhibit Na,K-ATPase and Na,H-exchanger in proximal tubules of hyperinsulinemic obese Zucker rats. The present study was designed to test the hypothesis that the defect in dopamine receptor function is a result of hyperinsulinemia in obese rats. We designed experiments to study D1 receptor function in obese Zucker rats treated with rosiglitazone, as it lowers plasma insulin by improving insulin sensitivity. A group of untreated lean and obese rats served as controls. Rosiglitazone treatment (10 mg/kg orally, 4 weeks) caused significant decreases in plasma insulin, blood glucose, and blood pressure while causing an increase in renal sodium excretion compared with untreated obese rats. In the isolated proximal tubules obtained from untreated lean rats, dopamine caused concentration-dependent inhibition of the Na,K-ATPase activity, but this inhibitory effect was absent in untreated obese rats. In rosiglitazone-treated obese rats, the inhibitory effect of dopamine on Na,K-ATPase was significantly restored. This was accompanied by a complete restoration of D1 receptor numbers in proximal tubular membranes of treated obese rats. In another set of experiments, treatment of primary proximal tubule epithelial cells in culture medium with insulin caused a significant decrease in the D1 receptor abundance, suggesting a direct role of insulin on D1 receptor regulation. We conclude that hyperinsulinemia causes downregulation of D1 receptor function and lowering of plasma insulin levels leads to restoration of renal D1 receptor function.


Key words: receptors, dopamine • hyperinsulinism • obesity • rats, Zucker




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
S. Tiwari, S. Riazi, and C. A. Ecelbarger
Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F974 - F984.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. A. Banday, F. R. Fazili, and M. F. Lokhandwala
Oxidative Stress Causes Renal Dopamine D1 Receptor Dysfunction and Hypertension via Mechanisms That Involve Nuclear Factor-{kappa}B and Protein Kinase C
J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1446 - 1457.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Zanchi, C. Perregaux, M. Maillard, D. Cefai, J. Nussberger, and M. Burnier
The PPAR{gamma} agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1228 - E1234.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Trivedi and M. F. Lokhandwala
Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats
Am J Physiol Renal Physiol, August 1, 2005; 289(2): F298 - F304.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
O. Khan, S. Riazi, X. Hu, J. Song, J. B. Wade, and C. A. Ecelbarger
Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone
Am J Physiol Renal Physiol, August 1, 2005; 289(2): F442 - F450.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. A. Banday, T. Hussain, and M. F. Lokhandwala
Renal dopamine D1 receptor dysfunction is acquired and not inherited in obese Zucker rats
Am J Physiol Renal Physiol, July 1, 2004; 287(1): F109 - F116.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Marwaha, A. A. Banday, and M. F. Lokhandwala
Reduced renal dopamine D1 receptor function in streptozotocin-induced diabetic rats
Am J Physiol Renal Physiol, March 1, 2004; 286(3): F451 - F457.
[Abstract] [Full Text]


Home page
HypertensionHome page
M. Trivedi, A. Marwaha, and M. Lokhandwala
Rosiglitazone Restores G-Protein Coupling, Recruitment, and Function of Renal Dopamine D1A Receptor in Obese Zucker Rats
Hypertension, February 1, 2004; 43(2): 376 - 382.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
C. V. Desouza, S. N. Murthy, J. Diez, B. Dunne, A. S. Matta, V. A. Fonseca, and D. B. McNamara
Differential Effects of Peroxisome Proliferator Activator Receptor-{alpha} and {gamma} Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 297 - 305.
[Abstract] [PDF]


Home page
HypertensionHome page
A. A. Banday, M. Asghar, T. Hussain, and M. F. Lokhandwala
Dopamine-Mediated Inhibition of Renal Na,K-ATPase Is Reduced by Insulin
Hypertension, June 1, 2003; 41(6): 1353 - 1358.
[Abstract] [Full Text] [PDF]